Skip to content

ENDO TOOLS THERAPEUTICS

Active
Public limited companyfounded 200817 yrs activeRue Clément Ader 10, 6041 Charleroi, BelgiumKBO/BCE: BE 0807.570.233
Summary

ENDO TOOLS THERAPEUTICS has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (€-15.06M) and a net result of €-9.93M. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 5% of 637 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Checked score

Score 2025
33 / 100
Weak
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability0=
Solvency0=
Growth32=
Track record100
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.09 against 0.68 in 2024; short-term debt: 358.7% and cash: 4.2% of total assets), and equity is negative.
Credit check for your own amount and term

Signals

Eight signals. The signal on the left, the evidence on the right.
lowers risk+raises riskneutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Sector 86
lower
← fewer bankruptcies more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
-294.9%
Return on assets
-194.5%
Age of the figures
9 mo
raises risk · Multiple establishment units
Several establishment units mean more fixed costs, and such companies fail more often than a company with one establishment.
KBO · establishment units
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 17 years 0 20 y
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €-15.06M
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-07-2026, 8 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
8 d early
2024
34 d early
2023
30 d early
2022
33 d early
2021
34 d early
2020
37 d early
2019
25 d early
← before the deadline after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, full schema

Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€-9.93M▼ 73.2%
2024 · €-5.74M
2018: €-1.57M 2019: €-2.03M 2020: €-2.29M 2021: €-2.45M 2022: €-3.55M 2023: €-4.88M 2024: €-5.74M
2018 → 2025
Working capital
€-16.67M▼ 2,075%
2024 · €-766k
2018: €4.79M 2019: €2.50M 2020: €8.16M 2021: €6.08M 2022: €6.40M 2023: €-90k 2024: €-766k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Equity€5.89M-€5.49M▼ 6.7%€609k▼ 88.9%€-5.13M€-15.06M▼ 194%
Operating result€-2.44M-€-3.50M▼ 43.6%€-4.86M▼ 38.7%€-5.49M▼ 13.0%€-5.37M▲ 2.2%
Net result€-2.45M-€-3.55M▼ 44.6%€-4.88M▼ 37.7%€-5.74M▼ 17.4%€-9.93M▼ 73.2%
Result per fiscal year
Operating resultNet result
€-10.00M€-7.50M€-5.00M€-2.50M€0Operating result 2021: €-2.44M€-2.44MNet result 2021: €-2.45M€-2.45MOperating result 2022: €-3.50M€-3.50MNet result 2022: €-3.55M€-3.55MOperating result 2023: €-4.86M€-4.86MNet result 2023: €-4.88M€-4.88MOperating result 2024: €-5.49M€-5.49MNet result 2024: €-5.74M€-5.74MOperating result 2025: €-5.37M€-5.37MNet result 2025: €-9.93M€-9.93M20212022202320242025€-10M€-7.5M€-5M€-2.5M€0Operating result 2023: €-4.86M€-4.9MNet result 2023: €-4.88M€-4.9MOperating result 2024: €-5.49M€-5.5MNet result 2024: €-5.74M€-5.7MOperating result 2025: €-5.37M€-5.4MNet result 2025: €-9.93M€-9.9M202320242025
The operating result stays negative: a loss of €5.37M in 2025 against €5.49M in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €5.11M
Fixed assets €3.46M ▲ 8.5%
Current assets €1.65M ▲ 1.5%
Key figures and ratios
2025 value · change against 2024
EBITDA
€-4.30M
2024 · €-4.59M
Cash flow
€-8.86M
2024 · €-4.83M
Solvency
-294.9%
2024 · -106.6%
Current ratio
0.09
2024 · 0.68
Quick ratio
0.04
2024 · 0.30
Debt to equity
-1.34
2024 · -1.94
ROA
-194.5%
2024 · -119.3%
Interest coverage
-0.93
2024 · -14.14
Debt
€20.17M
2024 · €9.94M
Debt ≤ 1 year
€18.32M
2024 · €2.39M
Debt > 1 year
€1.85M
2024 · €7.54M
Income taxes
€-60k
2024 · €-67k
Staff costs
€2.06M
2024 · €2.10M
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 57 lines
Balance sheet Code20242025
Assets
Total assets20/58€4.81M€5.11M
Fixed assets21/28€3.19M€3.46M
Intangible fixed assets21€2.74M€3.03M
Tangible fixed assets22/27€64k€63k
Plant, machinery and equipment23€59k€61k
Furniture and vehicles24€6k€2k
Financial fixed assets28€384k€363k
Current assets29/58€1.62M€1.65M
Amounts receivable after more than one year29€165k€183k
Other amounts receivable291€165k€183k
Stocks and contracts in progress3€908k€967k
Stocks30/36€908k€967k
Amounts receivable within one year40/41€258k€259k
Trade receivables40€143k€166k
Other amounts receivable41€115k€93k
Current investments50/53€0-
Cash at bank and in hand54/58€244k€217k
Deferred charges and accrued income490/1€50k€23k
Equity and liabilities
Total equity and liabilities10/49€4.81M€5.11M
Equity10/15€-5.13M€-15.06M
Contributions10/11€9.04M€9.04M=
Capital10€62k€62k=
Issued capital100€62k€62k=
Outside capital11€8.98M€8.98M=
Share premium1100/10€8.98M€8.98M=
Profit (loss) carried forward14€-14.17M€-24.10M
Amounts payable17/49€9.94M€20.17M
Amounts payable after more than one year17€7.54M€1.85M
Financial debts170/4€7.54M€1.85M
Amounts payable within one year42/48€2.39M€18.32M
Current portion of amounts payable after more than one year42€1.29M€15.83M
Financial debts43€16k€1.09M
Credit institutions430/8€16k-
Other loans439-€1.09M
Trade debts44€909k€1.24M
Suppliers440/4€909k€1.24M
Taxes, remuneration and social security45€173k€162k
Taxes450/3€2k€0
Remuneration and social security454/9€171k€162k
Accrued charges and deferred income492/3€4k€3k
Income statement Code20242025
Remuneration, social security and pensions62€2.10M€2.06M
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€902k€1.07M
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€13k-
Other operating charges640/8€1k€2k
Gross operating margin9900€-2.48M€-2.24M
Operating profit (loss)9901€-5.49M€-5.37M
Financial income75/76B€15k€5k
Recurring financial income75€15k€5k
Financial charges65/66B€325k€4.63M
Recurring financial charges65€325k€4.63M
Profit (loss) for the period before taxes9903€-5.80M€-9.99M
Income taxes67/77€-67k€-60k
Profit (loss) for the period9904€-5.74M€-9.93M
Profit (loss) for the period to be appropriated9905€-5.74M€-9.93M
Appropriation of the result
Profit (loss) to be appropriated9906€-14.17M€-24.10M
Profit (loss) brought forward from the previous period14P€-8.43M€-14.17M
Social balance
Average headcount (FTE)908721.119.4

The notes to these accounts (15 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
31-07
State Gazette act Resignations: DG International Consulting, CHAU Alexandre and 6 others
Appointments: DUFF Eugene Joseph Alexander, Capricorn Partners and 4 others · Permanent representatives: GESTIN Denis, DEGEER Philippe and 6 others · Capital increase36 facts ▸
  • General meeting, 13/07/2026
  • Capital increase, €177.421,67
  • Capital increase, €24.581.641,16
  • Capital increase, €10.000.000
  • Capital decrease, €24.101.436,61
  • Capital, €10.719.126,22
  • Share issue, Droits de Souscription Anti-Dilutifs, 42
  • Share issue, Droits de Souscription ESOP, 5479
  • Director resignation, DG International Consulting (administrateur non statutaire)
  • Director resignation, CHAU Alexandre (administrateur non statutaire)
  • Director resignation, NOLET DE BRAUWERE VAN STEENLAND Marc Emmanuel (administrateur non statutaire)
  • Director resignation, Mercury Leadership and Management (administrateur non statutaire)
  • +24 further facts in this act
23-07
NBB filing Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial Weakest financial yearnet €-9.93M
Net result drops to €-9.93M, the lowest in the series.
17-12
State Gazette act Reappointments: Deloitte Réviseurs d'Entreprises SRL, Old Mill Invest SRL and 6 others
Permanent representatives: Mathieu Bocquet, Philippe Degeer and 3 others14 facts ▸
  • General meeting, 24-06-2025
  • Auditor reappointment, Deloitte Réviseurs d'Entreprises SRL (statutory auditor)
  • Director reappointment, Old Mill Invest SRL (class B director)
  • Permanent representative, Mathieu Bocquet
  • Director reappointment, Mercury Leader and Management SRL (administrateur c)
  • Permanent representative, Philippe Degeer
  • Director reappointment, Alexandre Chau (director)
  • Director reappointment, Marc Nolet (class B director)
  • Director reappointment, DG International Consulting SRL (class B director)
  • Permanent representative, Denis Gestin
  • Director reappointment, Endomundi SRL (class A director)
  • Permanent representative, Vincent Huberty
  • +2 further facts in this act
27-06
NBB filing Annual accounts filed
fiscal year 2024 · full schema
2024
01-07
NBB filing Annual accounts filed
fiscal year 2023 · full schema
30-05
State Gazette act Registered office
Registered-office move2 facts ▸
  • Board meeting
  • Registered-office move, Rue Clément Ader 10, 6041 Charleroi
2023
28-06
NBB filing Annual accounts filed
fiscal year 2022 · full schema
2022
24-10
State Gazette act Capital & shares
Capital increase · Capital decrease · Capital8 facts ▸
  • General meeting, 03-10-2022
  • Capital increase, €146.881,89
  • Capital increase, €6.431.941,06
  • Capital decrease, €8.335.553,56
  • Capital, €61.500
  • Share issue, droits de souscription, A
  • Power of attorney, Conseil d'administration
  • Premium allocation, constitue à l'égal du capital la garantie des tiers et ne peut être réduit que par une décision de l'assemblée générale extraordinaire statuant conformément à l…
13-09
State Gazette act Appointment: MV Lifesciences SRL (class B director)
Permanent representative: Michel Vanbrabant3 facts ▸
  • General meeting, 27-06-2022
  • Director appointment, MV Lifesciences SRL (class B director)
  • Permanent representative, Michel Vanbrabant
06-07
State Gazette act Reappointment: ENDO TOOLS THERAPEUTICS (statutory auditor)
1 fact ▸
  • Auditor reappointment, ENDO TOOLS THERAPEUTICS
27-06
NBB filing Annual accounts filed
fiscal year 2021 · full schema
Show earlier events
06-01
State Gazette act Reappointment: Denis Gestin (statutory auditor)
2 facts ▸
  • General meeting, 23-06-2021
  • Auditor reappointment, Denis Gestin (statutory auditor)
2021
24-06
NBB filing Annual accounts filed
fiscal year 2020 · full schema
08-02
State Gazette act Capital & shares · Statutes amendment
Capital increase · Share issue · Capital8 facts ▸
  • General meeting, 23-12-2020
  • Capital increase, €373.294,95
  • Share issue, D, 1563
  • Capital, €1.818.230,61
  • Statutes amendment
  • Power of attorney, Sophie Maquet
  • Premium allocation, 7635517.05
  • Share subscription, souscrites en espèces et libérées à la souscription
2020
31-12
Financial Liquidity triplescurrent ratio 24.35
Current ratio from 8.22 to 24.35.
31-12
Financial Equity above €5MEq €8.34M ▲219%
Equity rises from €2.62M to €8.34M.
09-10
State Gazette act Appointments: Vincent Huberty, DG International Consulting and Endomundi srl
Permanent representatives: Denis Gestin, Vincent Huberty and Olivier Delporte · Resignation: Vincent Huberty (director) · Reappointments: ODMC bvba, Alexandre Chau and Marc Nolet de Brauwere van Steenland30 facts ▸
  • General meeting, 12-06-2019
  • Director appointment, Vincent Huberty (director)
  • Director appointment, DG International Consulting (director)
  • Director appointment, DG International Consulting (président du ca)
  • Permanent representative, Denis Gestin
  • Mandate compensation, Vincent Huberty
  • Mandate compensation, DG International Consulting
  • Mandate compensation, OMI sprl
  • Mandate compensation, ODMC bvba
  • Mandate compensation, New Breath sprl
  • General meeting, 15-06-2020
  • Director resignation, Vincent Huberty (director)
  • +18 further facts in this act
06-07
NBB filing Annual accounts filed
fiscal year 2019 · full schema
2019
21-06
NBB filing Annual accounts filed
fiscal year 2018 · full schema
2018
29-10
State Gazette act Resignation: BOCQUET Matthieu (director)
Appointments: Old Mill Invest (director) and MERCURY LEADERSHIP AND MANAGEMENT (director) · Permanent representatives: BOCQUET Matthieu and DEGEER Philippe Jean-Marie Léopold · Reappointment: Deloitte Reviseurs d'entreprises (statutory auditor)16 facts ▸
  • General meeting, 08-10-2018
  • Capital decrease, €1.186.988,63
  • Capital increase, €58.752,18
  • Capital increase, €226.649,67
  • Capital, €1.444.935,66
  • Director resignation, BOCQUET Matthieu (director)
  • Director appointment, Old Mill Invest (director)
  • Permanent representative, BOCQUET Matthieu
  • Director appointment, MERCURY LEADERSHIP AND MANAGEMENT (director)
  • Permanent representative, DEGEER Philippe Jean-Marie Léopold
  • Mandate compensation, Old Mill Invest
  • Mandate compensation, MERCURY LEADERSHIP AND MANAGEMENT
  • +4 further facts in this act
03-07
NBB filing Annual accounts filed
fiscal year 2017 · full schema
2017
29-12
State Gazette act Capital & shares
Capital increase · Capital decrease · Capital6 facts ▸
  • General meeting, 05-12-2017
  • Capital increase, €1.008.523,11
  • Capital decrease, €3.489.192,82
  • Capital, €2.346.522,44
  • Statutes amendment
  • Power of attorney, Conseil d'administration
05-07
NBB filing Annual accounts filed
fiscal year 2016 · full schema
15-06
State Gazette act Capital & shares
Capital increase · Share issue · Bank account9 facts ▸
  • General meeting, 24-05-2017
  • Capital increase, €1.002.150
  • Share issue, B, 306
  • Bank account, ING Banque, BE07 3630 6476 9566
  • Capital, €4.827.192,15
  • Statutes amendment
  • Power of attorney, Alexandre CHAU
  • Waiver of preemptive rights, Renonciation au droit de préférence
  • Par value, 840.85, EUR
2016
22-11
State Gazette act Capital & shares · Statutes amendment
Capital increase · Capital · Statutes amendment8 facts ▸
  • General meeting, 02-11-2016
  • Capital increase, €116.453,88
  • Capital, €3.195.778,2
  • Capital increase, €69.161,4
  • Capital increase, €560.102,55
  • Capital, €3.825.042,15
  • Statutes amendment
  • Bank account, BE57 3630 4724 8235
03-10
State Gazette act Statutes amendment
Capital · Power of attorney4 facts ▸
  • General meeting, 15-09-2016
  • Capital, €3.079.324,32
  • Statutes amendment
  • Power of attorney, Conseil d'administration
03-10
State Gazette act Resignations: Theodorus II, Sambrinvest Spin-off/Spin-out and 3 others
Appointments: New Breath SPRL (director) and Matthieu Bocquet (director)15 facts ▸
  • General meeting, 21-09-2016
  • Director resignation, Theodorus II (director)
  • Director resignation, Sambrinvest Spin-off/Spin-out (director)
  • Director resignation, Enreva (director)
  • Director resignation, Biotech Coaching (observateur)
  • Director resignation, Anne Prignon (observateur)
  • Director appointment, New Breath SPRL (director)
  • Director appointment, Matthieu Bocquet (director)
  • Board composition, Jacques Devière (director)
  • Board composition, ODMC SPRL (director)
  • Board composition, Alexandre Chau (director)
  • Board composition, Marc Nolet de Brauwere (director)
  • +3 further facts in this act
13-01
State Gazette act Appointment: Deloitte Réviseur d'Entreprises (statutory auditor)
2 facts ▸
  • General meeting, 26-06-2015
  • Auditor appointment, Deloitte Réviseur d'Entreprises (statutory auditor)
2013
29-07
State Gazette act Resignations: Jacques DEVIERE, Alain DELCHAMBRE and 4 others
Appointments: Jacques DEVIERE, Alexandre CHAU and 7 others · Capital increase · Capital19 facts ▸
  • General meeting, 28-06-2013
  • Capital increase, €2.500.000
  • Capital, €3.079.324,32
  • Statutes amendment
  • Director resignation, Jacques DEVIERE (director)
  • Director resignation, Alain DELCHAMBRE (director)
  • Director resignation, Olivier DELPORTE (director)
  • Director resignation, Theodorus II (director)
  • Director resignation, ENREVA (director)
  • Director resignation, SAMBRINVEST SPIN-OFF/SPIN-OUT SA (director)
  • Director appointment, Jacques DEVIERE (director)
  • Director appointment, Alexandre CHAU (director)
  • +7 further facts in this act
09-01
State Gazette act Capital & shares · Statutes amendment · Resignations & appointments
Capital increase · Capital decrease · Registered-office move10 facts ▸
  • General meeting, 13-12-2012
  • Capital increase, €237.349,84
  • Capital increase, €147.230,26
  • Capital increase, €90.119,59
  • Capital increase, €14.146,68
  • Capital increase, €14.146,68
  • Capital increase, €61.302,28
  • Capital decrease, €504.730,49
  • Registered-office move, 6041 Gosselies, rue Auguste Piccard 48, Biopark Incubator, Aéropole de Charleroi
  • Capital, €579.324,32
09-01
State Gazette act Capital & shares · Statutes amendment · Resignations & appointments
Share issue · Capital increase · Power of attorney12 facts ▸
  • General meeting, 13-12-2012
  • Share issue, warrants, 1155
  • Capital increase, €corresponding to the exercise of subscription rights
  • Power of attorney, Conseil d'Administration (représenté par deux administrateurs agissant conjointement)
  • Warrant attribution, warrants, 500
  • Warrant attribution, warrants, 478
  • Warrant attribution, warrants, 57
  • Warrant attribution, warrants, 60
  • Warrant attribution, warrants, 30
  • Warrant attribution, warrants, 30
  • Warrant exercise period, 30-10-2017, January and October of the 4th and 5th years after the offer
  • Issue premium, The difference between the capital increase amount and the subscription prices is allocated to the blocked account 'Prime d'émission', which constitutes a guara…
2012
08-10
State Gazette act Appointment: Alexandre Chau (managing director)
2 facts ▸
  • General meeting, 20-07-2012
  • Director appointment, Alexandre Chau (managing director)
08-10
State Gazette act Registered office
Registered-office move2 facts ▸
  • Board meeting, 03-09-2012
  • Registered-office move, Biopark Incubator, Aéropole de Charleroi, Rue Auguste Piccard 48 à 6041 Gosselies
2011
22-03
State Gazette act Appointments: Jacques DEVIERE, Alain DELCHAMBRE and 5 others
Permanent representatives: Françoise MAGERMAN, Maurice BERENGER and Sébastien LEMPLOY · Share issue · Capital increase17 facts ▸
  • General meeting, 15-02-2011
  • Share issue, warrants, 246
  • Capital increase, €169.759,48
  • Capital, €519.759,48
  • Statutes amendment
  • Director resignation, director
  • Director appointment, Jacques DEVIERE (director)
  • Director appointment, Alain DELCHAMBRE (director)
  • Director appointment, Olivier DELPORTE (director)
  • Director appointment, Theodorus II (director)
  • Permanent representative, Françoise MAGERMAN
  • Director appointment, ENREVA (director)
  • +5 further facts in this act
2010
28-07
State Gazette act Appointment: Maurice Berenger (managing director)
Resignation: Nicolas Cauche (managing director) · Director discharge · Power of attorney6 facts ▸
  • Board meeting, 16-12-2009
  • Director appointment, Maurice Berenger (managing director)
  • Director resignation, Nicolas Cauche (managing director)
  • Director discharge, Nicolas Cauche
  • Power of attorney, Olivier Belenger
  • Board resolution, ouverture du capital pour financer les développements d'Endomina, montant conditionné par l'acceptation des subsides de la Région Wallonne
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors
13 directors, no change since 2026
CAPRICORN PARTNERS
Administrateur non statutaire · since 13-07-2026 · Public limited company · perm. rep.: PINTELON Filip Geert Johan Dominiek
Current
DG International Consulting
Administrateur non statutaire · since 13-07-2026 · Private limited company · perm. rep.: Denis Gestin
Current
DUFF Eugene Joseph Alexander
Administrateur non statutaire · since 13-07-2026
Current
Lumine Capital Advisors
Administrateur non statutaire · since 13-07-2026 · Legal entity · perm. rep.: BOCQUET Matthieu
Current
SFPIM
Administrateur non statutaire · since 13-07-2026 · Legal entity · perm. rep.: PHILIPPE Isabelle Françoise Marie Serge
Current
Marc Nolet de Brauwere van Steenland
Director · since 12-06-2019
Current
7 other directors
Marc Nolet de Brauwere van Steeland
Administrateur non statutaire · since 28-06-2013
Current
NEW BREATH
Director · since 21-09-2016 · Legal entity
Not recently confirmed
Christophe Pagnoulle
Director · since 28-06-2013
Not recently confirmed
Jacques DEVIERE
Director · since 28-06-2013
Not recently confirmed
ODMC
Director · since 28-06-2013 · Legal entity
Not recently confirmed
SA SAMBRINVEST SPIN-OFF/SPIN-OUT
Director · since 28-06-2013 · Legal entity · perm. rep.: Sébastien LEMPLOY
Not recently confirmed
Maurice Berenger
Managing director · since 16-12-2009
Not recently confirmed
13-07-2026 CAPRICORN PARTNERS: Appointed as Administrateur non statutaire
13-07-2026 DG International Consulting: Reappointed as Administrateur non statutaire
13-07-2026 DUFF Eugene Joseph Alexander: Appointed as Administrateur non statutaire
13-07-2026 Lumine Capital Advisors: Appointed as Administrateur non statutaire
13-07-2026 SFPIM: Appointed as Administrateur non statutaire
Full history in the Timeline (52 changes) →
Location & real-estate footprint
Registered office, Charleroi · 2 establishment units since 2008
establishment approximate All 2 establishment units on the map
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Rue Clément Ader 106041 Charleroi
Ground area
1.0 ha
Building footprint
1,024 m²
Volume, LiDAR
13,845 m³
2 parcels, Brussels, Wallonia · tallest building 22.9 m, ±5 floors. Linked by address, not a title deed.
2 establishment units
ETT
Rue Clément Ader 10, 6041 CharleroiManufacture of medical and dental instruments and supplies
since 20082.174.966.464
Researchdreef 12, 1070 Anderlecht
Manufacture of medical and dental instruments and supplies
since 20162.257.760.122
2 parcels
Wallonia 1 (50%) Brussels 1 (50%)
Parcel (capakey) Region Area Buildings Height / fl.
52028B0295/02C000 Wallonia 7,830 m² - -
21307F0170/00A003 Brussels 2,276 m² 1 · 1,024 m² 22.9 m · 5 fl.
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Statutory auditor

1 auditor
SRL DELOITTE Réviseurs d'EntreprisesCurrent
Statutory auditor
24-06-2025 → present
Show 3 earlier auditors
Deloitte Réviseur d'Entreprises
Statutory auditor
succeeded by Deloitte Réviseurs d'Entreprises in 2018
26-06-2015 → 08-10-2018
Deloitte Réviseurs d'Entreprises
Auditor
succeeded by Denis Gestin in 2021
08-10-2018 → 23-06-2021
Denis Gestin
Statutory auditor
succeeded by SRL DELOITTE Réviseurs d'Entreprises in 2025
23-06-2021 → 24-06-2025

Articles of association

Purpose
La société a pour objet tant en Belgique qu'à l'étranger pour compte propre ou pour compte de tiers ou en participation avec des tiers 1. la recherche, l'étude, la conception, la…
Full purpose

La société a pour objet tant en Belgique qu'à l'étranger pour compte propre ou pour compte de tiers ou en participation avec des tiers 1. la recherche, l'étude, la conception, la réalisation, la fabrication, la mise au point de matériel endoscopique, de diagnostic, thérapeutique et autres; 2. le développement l'étude, la conception, la réalisation et la fabrication de logiciels permettant l’ exploitation des méthodes sub 1 ainsi que de logiciels destinés à la recherche clinique; 3. la production, la promotion, l'achat et la vente, la sous-traitance, l'importation, l'exportation en gros, demi-gros ou en détail, la représentation et la maintenance dans les domaines cités sub 1 et 2 ainsi que d’une manière générale de tout matériel médical; 4. la consultance, le parrainage et le partenariat dans les objets qui précèdent; 5. le dépôt et l'exploitation des brevets, dessins et modèles, marques et autres droits intellectuels et patrimoniaux issus des objets qui précèdent; 6. La formation, l’information, la publication et l’édition sur tous supports en relation avec les objets qui précèdent. Dans le cadre du développement de formations individuelles et collectives, l'organisation et l'animation de stages et de séminaires et la participation à des conférences, des cours, et les journées d'étude concernant les objets qui précèdent ; ces stages, séminaires, conférences, cours et études pouvant être organisés à l'étranger. 7. La recherche, l’étude, la conception, l’achat et la vente de tous types d’appareillages et accessoires nécessaires à la fabrication, la transformation, la conservation et l’utilisation de ces produits. La société peut pourvoir à l'administration, à la supervision et au contrôle de toutes sociétés liées ou avec lesquelles il existe un lien de participation et toutes autres, et consentir tous prêts ou garanties à celles-ci, sous quelque forme et pour quelque durée que ce soit. La société peut accomplir toutes opérations généralement quelconques, commerciales, industrielles, financières, mobilières ou immobilières, se rapportant directement ou indirectement à son objet. Elle peut s'intéresser par voie d'apport, de souscription, de prise de participation, de fusion, ou toute autre forme d'investissement en titres ou droits mobiliers, dans toutes affaires, entreprises, fondations, associations ou sociétés ayant un objet identique, analogue, similaire ou connexe, ou qui sont de nature à favoriser le développement de son entreprise, à lui procurer des matières premières ou à faciliter l’écoulement de ses produits. De manière générale, la société peut réaliser son objet directement ou indirectement et notamment conclure toute convention d'association, de rationalisation, de collaboration, tout contrat de travail ou d'entreprise, prêter son concours financier sous quelque forme que ce soit, exécuter tous travaux et étude pour toute entreprise, association ou société à laquelle elle se sera intéressée ou à laquelle elle aura apporté son concours financier, vendre, acheter, cautionner, donner à bail ou prendre en location tout bien corporel ou incorporel, mobilier ou immobilier, donner à bail ou affermer tout ou partie de ses installations, exploitations et son fonds de commerce.

Structure & network

Connections & network

33 connected companies
Marc Nolet de Brauwere van Steeland, Shared director, links 5 companies MNMarc Nolet deBrauwere van…ISTAR MEDICAL, via Marc Nolet de Brauwere van Steeland IMISTAR MEDICALALIAXIS, via Marc Nolet de Brauwere van Steeland AALIAXISBioSenic, via Marc Nolet de Brauwere van Steeland BBioSenicETEX, via Marc Nolet de Brauwere van Steeland EETEXSPREDS, via Marc Nolet de Brauwere van Steeland SSPREDS6K venture capital, Shared director 6V6K venturecapitalASSOCIATION VINCOTTE NUCLEAR, Shared director AVASSOCIATIONVINCOTTE NUCLEARAZIMUT Entreprendre, Shared director AEAZIMUTEntreprendreBePharBel Manufacturing, Shared director BMBePharBelManufacturingBIOPOLE ULB - CHARLEROI en abrégé BUC, Shared director BUBIOPOLE ULBCHARLEROI en…BRUSSELS SOUTH CHARLEROI AIRPORT, Shared director BSBRUSSELS SOUTHCHARLEROI…FONDATION ULB, Shared director FUFONDATION ULBFONDS DE CAPITAL A RISQUE 2020, Shared director FDFONDS DE CAPITALA RISQUE 2020ENDO TOOLS THERAPEUTICS ENDO TOOLSTHERAPEUTICS0807.570.233
Shared directors
Linked via shared directors
Show 29 more companies with a shared director
6K venture capital
Shared director
AZIMUT Entreprendre
Shared director
FONDATION ULB
Shared director
IMBC 2020
Shared director
IMBC CAPITAL RISQUE
Shared director
ImmunXperts
Shared director
SAMBRELEASE
Shared director
Starter Fund
Shared director
ARKITE
Shared corporate director
CAPRICORN ICT ARKIV
Shared corporate director
FEops
Shared corporate director
icometrix
Shared corporate director
PUNCH POWERTRAIN
Shared corporate director
Sensolus
Shared corporate director
Spectricity
Shared corporate director

Capital and shareholders

Shareholders according to the acts
After the capital increase act of 08-02-2021 ↗
  • Chagral Invest
  • Epimede
  • SFPI
  • Pagnoulle
  • Chau
  • Delchambre
  • Delporte
  • Huberty
  • White Fund
  • Hi Invest
  • Delloye
  • Carakehian
  • Moorkens
After the capital increase act of 15-06-2017 ↗
  • Société fédérale de participations et d'investissement
After the capital increase act of 29-07-2013 ↗
  • Marc Nolet de Brauwere 1,041 shares
  • Christophe Pagnoulle 116 shares

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 31-07-2026 Capital increase of 177,421.67 EUR · to 238,921.67 EUR · 23,737 new shares · in kind
  2. 31-07-2026 Capital increase of 24,581,641.16 EUR · to 24,820,562.83 EUR · no new shares · from reserves
  3. 31-07-2026 Capital increase of 10,000,000 EUR · to 34,820,562.83 EUR · 12,787 new shares · in cash
  4. 31-07-2026 Capital reduction of 24,101,436.61 EUR · to 10,719,126.22 EUR · to absorb losses
  5. 24-10-2022 Capital increase of 146,881.89 EUR · to 1,965,112.50 EUR · 615 new shares
  6. 24-10-2022 Capital increase of 6,431,941.06 EUR · to 8,397,053.56 EUR · no new shares · from reserves
  7. 24-10-2022 Capital reduction of 8,335,553.56 EUR · to 61,500 EUR · to absorb losses
  8. 08-02-2021 Capital increase of 373,294.95 EUR · to 1,818,230.61 EUR · 1,563 new shares
Show 19 older capital entries
  1. 29-10-2018 Capital reduction of 1,186,988.63 EUR · to 1,159,533.81 EUR · to absorb losses
  2. 29-10-2018 Capital increase of 58,752.18 EUR · to 1,218,285.99 EUR · 246 new shares
  3. 29-10-2018 Capital increase of 226,649.67 EUR · to 1,444,935.66 EUR · 949 new shares
  4. 29-12-2017 Capital increase of 1,008,523.11 EUR · to 5,835,715.26 EUR · from reserves
  5. 29-12-2017 Capital reduction of 3,489,192.82 EUR · to 2,346,522.44 EUR · to absorb losses
  6. 15-06-2017 Capital increase of 1,002,150 EUR · to 4,827,192.15 EUR · 306 new shares
  7. 22-11-2016 Capital increase of 116,453.88 EUR · to 3,195,778.20 EUR · 122 new shares · in kind
  8. 22-11-2016 Capital increase of 69,161.40 EUR · to 3,264,939.60 EUR · 132 new shares · in cash
  9. 22-11-2016 Capital increase of 560,102.55 EUR · to 3,825,042.15 EUR · 1,069 new shares · in cash
  10. 03-10-2016 Capital stated in the act · 3,079,324.32 EUR · 3,226 shares
  11. 29-07-2013 Capital increase of 2,500,000 EUR · to 3,079,324.32 EUR · 1,157 new shares
  12. 09-01-2013 Capital increase of 237,349.84 EUR · to 757,109.32 EUR · 453 new shares
  13. 09-01-2013 Capital increase of 147,230.26 EUR · to 904,339.58 EUR · 281 new shares
  14. 09-01-2013 Capital increase of 90,119.59 EUR · to 994,459.17 EUR · 172 new shares
  15. 09-01-2013 Capital increase of 14,146.68 EUR · to 1,008,605.85 EUR · 27 new shares
  16. 09-01-2013 Capital increase of 14,146.68 EUR · to 1,022,752.53 EUR · 27 new shares
  17. 09-01-2013 Capital increase of 61,302.28 EUR · to 1,084,054.81 EUR · 117 new shares
  18. 09-01-2013 Capital reduction of 504,730.49 EUR · to 579,324.32 EUR · “sans annulation de titres”
  19. 22-03-2011 Capital increase of 169,759.48 EUR · to 519,759.48 EUR · 324 new shares

Similar companies · same sector, comparable size

Of 10,451 companies in sector 86995 we hold annual accounts for 886. 483 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Company data · Crossroads Bank

Identification
Legal formPublic limited company
Founded29-10-2008
Fiscal year end31-12
Activities, NACEBEL 2025
72109Other research and development on natural sciences
86995Nutrition and dietetics services
32500Manufacture of medical and dental instruments and supplies
74999Other professional, scientific and technical activities
Sources
Crossroads Bank for EnterprisesNational Bank · 17 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.

Contact details

4 entries
Enterprise
E-mail:info@endotools.be
Enterprise
Phone:+3271919409
Enterprise
Phone:071 91 94 09
Establishment Charleroi 2.174.966.464